Charles River Showcases Innovations at Neuroscience 2024 Event
Charles River Takes Center Stage at Neuroscience 2024
Charles River Laboratories International, Inc. (NYSE: CRL) is set to share its wealth of knowledge and the latest innovations in neuroscience at the highly anticipated Neuroscience 2024 annual meeting of the Society for Neuroscience (SfN). The event promises to unite some of the brightest minds in neuroscience, where Charles River will be showcasing a total of 18 scientific posters, developed by both their team and in collaboration with clients.
A Commitment to Advancing Neuroscience
At the forefront of this year’s meeting, Charles River reaffirms its commitment to transforming neuroscience research. Antti Nurmi, Ph.D., MSc, the General Manager of CNS Pharmacology at Charles River, emphasizes the organization’s mission to provide translational expertise that enhances preclinical models and innovative drug discovery processes. By doing so, they aim to improve patient outcomes worldwide.
Significant Contributions to Drug Discovery
Advancements in genetics, pathology, biomarkers, and endpoints are pivotal in fostering progress within neuroscience drug discovery. During the conference, Charles River’s experts will not only present posters but also engage in discussions concerning recent breakthroughs and their applications in treating neurodegenerative conditions. Some of the noteworthy presentations include:
- Establishment and validation of an in vitro co-culture model to study myelination using human iPSC-derived glutamatergic neurons and oligodendrocytes presented by Malika Bsibsi.
- An iPSC-derived neuroinflammation in vitro model of neurons and glial cells also presented by Malika Bsibsi.
Driving Discussion Around ALS Research
On the morning of a key conference day, Charles River's scientific experts will hold an essential discussion regarding the latest findings and their implications for ALS research. The session, scheduled for Monday, will see notable scientists such as Susanne Back, Ph.D., and Philip Mitchell, Ph.D., as they explore how cellular and animal models can reflect the complexities of disease pathology.
Collaborative Efforts and Recent Announcements
Charles River's dedicated team of nearly 200 neuroscientists spans drug discovery and development, providing comprehensive support from foundational research through to regulatory stages. Since 2018, their contributions have supported 80% of newly approved neuroscience medications by the United States Food & Drug Administration (FDA).
Recent Innovations Making Waves
Among their latest strides, Charles River is proud to highlight a strategic collaboration with CEBINA that aims to propel groundbreaking neuroscience research. Additionally, through their latest integration of Insightec’s low-frequency ultrasound technology, precise therapeutic delivery methods are being established, which can reach deeply seated brain structures. Utilizing their AI-powered solution, Logica®, they are transforming drug discovery processes to accelerate critical brain disease research alongside partners like H. Lundbeck A/S.
Engage with Charles River at Neuroscience 2024
A detailed schedule of Charles River's contributions and activities throughout Neuroscience 2024 can be found online for those interested in their vast array of offerings. Their team will also be available at Booth #417, welcoming professionals eager to discuss neuroscience research, drug discovery innovations, and potential collaborations.
Frequently Asked Questions
What is the main focus of Charles River at Neuroscience 2024?
Charles River will present 18 scientific posters and lead discussions on advancements in neuroscience drug discovery and neurodegenerative disease research.
Who are the key speakers from Charles River at the event?
Notable speakers will include Antti Nurmi, Susanne Back, Ph.D., and Philip Mitchell, Ph.D., who will share their insights during presentations and discussions.
How does Charles River contribute to drug discovery?
Charles River supports drug discovery by offering comprehensive services and collaborating on research, which has led to significant contributions, particularly in neuroscience.
What recent collaborations has Charles River engaged in?
Recently, they announced a strategic collaboration with CEBINA and integrated Insightec’s ultrasound technology to enhance drug delivery methods.
Where can I find more information about Charles River's activities at the conference?
Details regarding Charles River's schedule and activities can be accessed online, providing insights into their presentations and participation at Neuroscience 2024.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Alpha Cognition's New Leadership: Aiming for Breakthroughs in Neurodegenerative Therapy
- Scout & Cellar's B Corp Certification: A Milestone in Winemaking
- Vale's Strategic Expansion of Copper Production and Investments
- Growth of Secure Logistics Market Driven by AI Innovations
- Manganese Mining Sector Set for Dramatic Growth by USD 10.94 Billion
- 79North's Strategic Debt Settlement: An Overview
- OpenSea Securities Investigation: What You Need to Know
- Avient Set to Host its Q3 2024 Earnings Call & Webcast
- AI Innovations Shaping the Future of Frozen Food Industry
- NexPoint Real Estate Finance to Discuss Q3 Earnings in Call
Recent Articles
- FrontView REIT, Inc. Successfully Closes Initial Offering
- NorthStar Medical Radioisotopes Engages in Industry Summit
- DeepCure Showcases Powerful New Treatment for RA That Outshines Etanercept
- Join the Excitement at the Annual Yugabyte Distributed SQL Summit
- Unlocking Information Quality: A Symposium for Everyone
- Vir Biotechnology's Upcoming Engagements and Innovations in Healthcare
- The Growing IT Skills Gap: Insights for UK Businesses
- Unlocking Your Business Potential: The PagerDuty Advantage
- Markel Group Plans Exciting 2025 Reunion with Engaging Events
- Chinese Central Bank Embarks on Bond Purchasing Strategy
- Tradeswomen Conference Unites Female Iron Workers in a Major Event
- Brian Scott Takes the Helm as CFO and COO at AMN Healthcare
- New Insights on Targeting Toxic Gain of Function Mutations
- VyStar Credit Union Expands Workforce with New Opportunities
- Ultragenyx Pharmaceutical Shows Promise in Gene Therapy Progress
- Impact of Healthcare Costs on American Voting in 2024
- NASA's New Astrophysics Missions Set to Unlock Cosmic Mysteries
- StandardAero's IPO Fuels New Financial Strategies and Growth
- Sustainability Education: A Must-Have for America’s Schools
- TMTG Faces Legal Challenges Amid Expansion Efforts
- Canadian Physician Consensus: Urgent Need for AI Regulations
- SWK Holdings Corporation Faces Board Change as Pennington Resigns
- Security Camera Demand Grows Amid Election Integrity Concerns
- Virpax Pharmaceuticals Expands Financial Negotiation Options
- euNetworks Unveils Advanced Fibre Route Boosting Connectivity
- Sportradar Appoints Michael C. Miller as Legal Chief
- Discover the Latest Innovations with Oura Ring 4 Launch
- SMART Global Holdings Announces 2025 Shareholder Meeting Plans
- TCarta Marine Enhances Maritime Safety with Satellite Solutions
- Alzamend Neuro Secures $6.5 Million Through ATM Offering
- Zyxel Launches Advanced Wi-Fi 7 Gateways for Service Providers
- Ultragenyx Advances Gene Therapy Study with Positive Results
- Transforming TV Advertising: The Launch of Annika Audience™
- Understanding the Impacts of Federal Reserve's Losses
- Starbucks Takes Bold Steps Towards a Sustainable Coffee Future
- Market Volatility: U.S. Stocks Decline Amid Sector Losses
- Phreesia and Ad Council's Impact on Mental Health Engagement
- CALQUENCE® Receives Priority Review in the US for MCL Treatment
- Herbalife Achieves GUINNESS WORLD RECORDS Title in Fitness Event
- D-Wave Evolves with Service-Level Agreements for Quantum Cloud
- Jabil's Strategic Acquisition of Mikros Technologies for Enhanced AI Cooling
- Aldeyra Therapeutics Advances Reproxalap for Dry Eye Disease
- Harrow Revives TRIESENCE®: A Breakthrough for Eyecare
- Laser Photonics and Brokk Showcase Innovative Robotic Solutions
- Handling Cyberbullying: Empowering Teens in Modern Times
- Vecima Networks Enhances Connectivity During Crisis Response
- TransAct Technologies Gears Up for Major Events in Las Vegas
- CDK Unveils Innovative Certification Program for Dealerships
- Onconetix Secures $2 Million in Financing for Growth Plans
- GoldenTV Unveils Exciting New Programs for 2024-2025 Season